DRD2 and neurodegenerative disease: Furthermore, methylation of the DRD2 promoter in leucocytes has been shown to differ between DLB and PD58, while D2 receptor density has been shown to be significantly reduced in the temporal cortex of DLB patients, but not AD59, suggesting that the DRD2 locus may harbour markers that could distinguish between these neurodegenerative diseases.